CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.02.20	Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST (Businesswire)
18.02.20	Cellectis and Servier Expand Collaboration on UCART19 Products (Businesswire)
15.01.20	First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia (Businesswire)
06.01.20	Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery (Businesswire)
02.12.19	1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Businesswire)
20.11.19	Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells (Businesswire)
13.11.19	Cellectis Publishes Creation of "Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications (Businesswire)
06.11.19	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 (Businesswire)
31.10.19	Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST (Businesswire)
29.10.19	First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma (Businesswire)
01.10.19	Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates (Businesswire)
06.08.19	Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 (Businesswire)
08.07.19	Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way (Businesswire)
26.06.19	Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 (Businesswire)
07.05.19	Cellectis Reports Financial Results for First Quarter 2019 (Businesswire)
02.04.19	FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients (Businesswire)
11.03.19	Cellectis Reports 4th Quarter and Full Year 2018 Financial Results (Businesswire)
07.03.19	Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio (Businesswire)
25.02.19	Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry (Businesswire)
10.12.18	Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing (Businesswire)
13.11.18	Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 (Businesswire)
19.09.18	CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board (Businesswire)
18.09.18	Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP (Businesswire)
02.08.18	Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer (Businesswire)
01.08.18	Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 (Businesswire)
27.06.18	Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 (Businesswire)
12.06.18	Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports (Businesswire)
04.06.18	FDA Grants Cellectis IND Approval for UCART22 in B-ALL (Businesswire)
23.05.18	INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
22.05.18	Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
21.05.18	Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
15.05.18	Calyxt Announces Launch of Proposed Follow-On Offering (Businesswire)
10.05.18	Cellectis to Present Data at the 2018 ASGCT Annual Meeting (Businesswire)
07.05.18	Cellectis Reports 1st Quarter 2018 Financial Results (Businesswire)
02.05.18	Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) (Businesswire)
01.05.18	Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome (Businesswire)
11.04.18	Cellectis to Present Data at the 2018 AACR Annual Meeting (Businesswire)
10.04.18	Cellectis Announces Closing of Follow-On Offering (Businesswire)
05.04.18	Cellectis Announces Pricing of Follow-On Offering (Businesswire)
03.04.18	Cellectis Announces Launch of Follow-On Offering (Businesswire)
03.04.18	Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies (Businesswire)
13.03.18	Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor (Businesswire)
12.03.18	Cellectis Reports 4th Quarter and Full Year 2017 Financial Results (Businesswire)
08.03.18	Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting (Businesswire)
13.02.18	Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells (Businesswire)
06.02.18	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
08.01.18	Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.01.18	Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT (Businesswire)
13.12.17	Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials (Businesswire)
04.12.17	Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten